Effective treatment for long COVID is an urgent unmet need
Second, a larger trial involving After high-risk or moderate-risk exposure to Covid-19, hydroxychloroquine did not prevent illness compatible with Covid-19 or confirmed infection when used as postexposure prophylaxis within 4 Methods
Understanding the uses and side effects
The drug gained attention when early reports suggested it might benefit COVID-19 patients
Last week, the WHO temporarily They found 14 relevant studies: 12 studies of chloroquine or hydroxychloroquine used to treat COVID-19 in 8569 adults; two studies of hydroxychloroquine to stop COVID-19 in 3346 adults who had been exposed to the virus but had no symptoms of infection
The drug hasn’t been effective enough in treating COVID-19 to be accepted as a mainstream treatment recommendation
In Feb, 2020, we conducted the first single-center, randomized, open-label clinical trial to evaluate the
Methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, and LILACS (January 2019 to March 2021) for patients aged 18
Hydroxychloroquine (HCQ) has received worldwide attention as a potential treatment for coronavirus disease 2019 (COVID-19) because of positive results from small studies
As of January 3, 2021, the infection was reported from 222 countries globally, 8,25,79,768 patients have been confirmed to have COVID-19, and 18,18,849 of them have died